Healthcare products
Child Health
Deficiency States and Supplementation
Dermatological Health
Pain treatment
Gastrointestinal Health
Genitourinary Health
Cardiorespiratory Health
Corticotherapy
Oral-Pharyngeal Health
Fluid Therapy
CNS Treatment
FDA has approved intravenous fosfomycin for the treatment of cUTI
FDA has approved intravenous fosfomycin for the treatment of cUTI
On October 22, 2025, the U.S. Food and Drug Administration (FDA) approved intravenous fosfomycin for the treatment of complicated urinary tract infections (cUTI).
Laboratorios ERN expresses its satisfaction with the recent approval by the U.S. Food and Drug Administration (FDA) of intravenous fosfomycin for the treatment of patients aged 18 years and older with complicated urinary tract infection (cUTI), including acute pyelonephritis.
This milestone represents a significant advancement in access to innovative therapeutic options for adult patients with complicated urinary tract infections, now also in the United States.
It is worth noting that Laboratorios ERN played a key role as the U.S. sponsor for the introduction of this molecule before transferring the rights to Meitheal Pharmaceuticals, which becomes a strategic partner for its commercialization in the coming years.
The FDA approval was based on data from the ZEUS study, a multinational, double-blind clinical trial that included 464 hospitalized adults with complicated urinary tract infection, including acute pyelonephritis. This study compared fosfomycin 6 grams administered intravenously every 8 hours with piperacillin/tazobactam 4.5 grams administered intravenously every 8 hours for 7 days of treatment, allowing a maximum of 14 days in patients with bacteremia.
Intravenous fosfomycin demonstrated its efficacy with an overall success rate — defined as clinical cure plus microbiological eradication — in 63.5% of treated patients, compared to 55.6% in those treated with piperacillin/tazobactam.
In conclusion, intravenous fosfomycin is considered an intravenous therapeutic option with a differentiated mechanism of action for patients with severe infections caused by Enterobacterales. Laboratorios ERN wishes to convey its best wishes to the Meitheal Pharmaceuticals team for the successful future launch of this medicine.
noticias relacionadas
Laboratorios ERN joins the Fundación Empresa y Clima (FEC) as a Silver member
We are proud to announce that Laboratorios ERN has officially joined the Fundación Empresa y Clima (FEC) as a Silver member, reinforcing our commitment to climate action and global sustainability. This alliance allows us to become part of a business community committed to the transition toward a low-carbon economy, alongside other companies that share the […]
ERN Laboratories supports research into pediatric rare diseases at Sant Joan de Déu Hospital in Barcelona.
During 2026, ERN Laboratories will allocate €1 for each unit sold of Astenolit Infantil, a nutritional supplement designed to support children’s energy levels and immune defenses, to benefit pediatric rare disease research at Sant Joan de Déu. This initiative is part of ERN Laboratories’ longstanding commitment to pediatrics and child health, supporting projects that contribute […]
Ernamín at the 55th Congress of the Spanish Society of Nephrology
From October 16–18, the 55th edition of the Congress of the Spanish Society of Nephrology (SEN) took place in Oviedo. For the first time, and following the launch of Ernamín, ERN Laboratories participated as a collaborator in the event, with a stand in the commercial exhibition area and by organizing a technical forum featuring high-level […]
Incremental Drug Innovation: A Priority Focus for Laboratorios ERN
David Solanes López, General Manager of Laboratorios ERN, was appointed Academician of the Royal Academy of Pharmacy of Catalonia on October 6, 2025, in the industrial section. Solanes dedicated his induction speech to incremental innovation, an area closely linked to his professional career and to Laboratorios ERN’s commitment to developing solutions that improve patients’ lives. […]
FDA has approved intravenous fosfomycin for the treatment of cUTI
On October 22, 2025, the U.S. Food and Drug Administration (FDA) approved intravenous fosfomycin for the treatment of complicated urinary tract infections (cUTI). Laboratorios ERN expresses its satisfaction with the recent approval by the U.S. Food and Drug Administration (FDA) of intravenous fosfomycin for the treatment of patients aged 18 years and older with complicated […]